Prospects for Universal Influenza Virus Vaccine
Open Access
- 1 April 2006
- journal article
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 12 (4) , 569-574
- https://doi.org/10.3201/eid1204.051020
Abstract
The current vaccination strategy against influenza A and B viruses is vulnerable to the unanticipated emergence of epidemic strains that are poorly matched by the vaccine. A vaccine that is less sensitive to the antigenic evolution of the virus would be a major improvement. The general feasibility of this goal is supported by studies in animal models that show that immunologic activities directed against relatively invariant viral determinants can reduce illness and death. The most promising approaches are based on antibodies specific for the relatively conserved ectodomain of matrix protein 2 and the intersubunit region of hemagglutinin. However, additional conserved determinants for protective antibodies are likely to exist, and their identification should be encouraged. Most importantly, infection and current vaccines do not appear to effectively induce these antibodies in humans. This finding provides a powerful rationale for testing the protective activity of these relatively conserved viral components in humans.Keywords
This publication has 43 references indexed in Scilit:
- Universal Influenza B Vaccine Based on the Maturational Cleavage Site of the Hemagglutinin PrecursorJournal of Virology, 2005
- Influenza Type A Virus Escape Mutants Emerge In Vivo in the Presence of Antibodies to the Ectodomain of Matrix Protein 2Journal of Virology, 2005
- Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeysVaccine, 2004
- Mapping the Antigenic and Genetic Evolution of Influenza VirusScience, 2004
- InfluenzaThe Lancet, 2003
- Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2Vaccine, 2003
- Predicting the Evolution of Human Influenza AScience, 1999
- Evaluation of Live Attenuated Influenza Vaccines in Children 6-18 Months of Age: Safety, Immunogenicity, and EfficacyThe Journal of Infectious Diseases, 1996
- Antibody response to the M2 protein of influenza A virus expressed in insect cellsJournal of General Virology, 1993
- Cytotoxic T-Cell Immunity to InfluenzaNew England Journal of Medicine, 1983